B
Bull
Bull · 25%SAGE
$14.56
情境價格
$8.680
-0.020 (-0.23%)收盤時
Loading chart…
- High
- 8.740
- Open
- 8.740
- VWAP
- 8.70
- Vol
- 22.70M
- Mkt Cap
- 643.35M
- Low
- 8.680
- Amount
- 197.48M
- EV/EBITDA, TTM
- 0.42
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Analyst Ratings (15)
0.00% downside
Buy
14 Buy
1 Hold
0 Sell
Current: 8.68
最低
5.00
平均
8.68
最高
12.00
Scotiabank
Sector Perform
$9.20
2025-07-07
Scotiabank
2025-07-07
目標價
$9.20
Sector Perform
JPMorgan
Neutral
$11
2025-06-22
JPMorgan
2025-06-22
目標價
$11
Neutral
Baird
Neutral
$9
2025-06-21
Baird
2025-06-21
目標價
$9
Neutral
Piper Sandler
Neutral
$9
2025-06-18
Piper Sandler
2025-06-18
目標價
$9
Neutral
BofA
No Rating
$12
2025-06-18
BofA
2025-06-18
目標價
$12
No Rating
估值指標
The current forward P/E ratio for SAGE Therapeutics Inc (SAGE) is -1.96, compared to its 5-year average forward P/E of -3.49.
Alphio AI Price Scenarios for SAGE
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
8.506-24Yahoo FinanceSage Potash Prepares for 2026 Drilling Program
8.507-31NewsfilterSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
8.507-28NewsfilterSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
9.007-25NASDAQ.COMBiogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment
9.007-24GlobenewswireZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
SAGE FAQ — answered by Alphio AI
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
15 analysts cover SAGE: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.68.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。